Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV 및 mRNA-1273을 사용한 SARS CoV-2에 대한 이종 면역의 면역원성과 반응성Article Published on 2022-08-162022-09-11 Journal: Cell Reports Medicine [Category] SARS, 변종, 진단, 치료기술, [키워드] Ad5-nCoV analyzed Anti-spike Antibody Response BBIBP-CorV ChAdOx1 ChAdOx1 vaccine ChAdOx1-S Cohort Combination coronavirus disease Coronavirus disease 2019 Coverage COVID-19 evaluate Heterologous heterologous vaccination heterologous vaccine highest homologous humoral Humoral response IgG immunization immunogenicity Immunoglobulin Immunoglobulin G information Messenger RNA mRNA mRNA-1273 nCoV Neutralizing antibodies observation observé omicron Omicron variant Participants platform provide reactogenicity Region SARS CoV-2 SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events Sputnik V Support titers vaccination Vaccine virus neutralizing titer virus neutralizing titers [DOI] 10.1016/j.xcrm.2022.100706 PMC 바로가기 [Article Type] Article
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens Research Published on 2022-08-112022-10-05 Journal: Nature Communications [Category] SARS, 치료기술, [키워드] Analysis Antigen BNT162b2 CD4 T-cell CD8 T-cell Cellular immune response ChAdOx1-nCoV-19 Cohort Combination combinations Comparative COVID-19 vaccine FIVE healthy individuals Heterologous highest homologous humoral Immunity induce mRNA-1273 reactogenicity regimen regimens SARS-CoV-2 T-cell the vaccine vaccination Vaccination strategy Vaccine [DOI] 10.1038/s41467-022-32321-0 [Article Type] Research
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanismsSARS-CoV-2 RNA 의존성 RNA 중합효소의 돌연변이는 별개의 메커니즘으로 렘데시비르에 대한 내성을 부여합니다Article Published on 2022-08-032022-09-11 Journal: Science Translational Medicine [Category] SARS, 변종, 유전자 메커니즘, 치료기술, 치료제, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Antiviral betacoronaviruses biochemical analysis biochemical pathway clinical settings Concentration consensus sequence consensus sequences coronavirus Critical defined demonstrated drug Drug administration Factor food Genetic greater GS-441524 half-maximal effective concentration Hepatitis homologous Increases increases in infections Lineage mechanism motif murine hepatitis virus Mutation nonstructural protein 12 nonsynonymous mutation Nonsynonymous mutations Nsp12 nucleoside overcome parent nucleoside passages phenotypic Prevent promote RdRP RDV Remdesivir Replication RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 RdRp Sequence analysis Ser severe acute respiratory syndrome Coronavirus Substitution substitutions substrate the SARS-CoV-2 to define Treatment triphosphate uridine triphosphate viral lineage [DOI] 10.1126/scitranslmed.abo0718 PMC 바로가기 [Article Type] Article
Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients중증급성호흡기증후군 코로나바이러스 2 간 이식 환자에서 동종 메신저 RNA 백신 3차 접종에 대한 항체 반응Article Published on 2022-08-012022-09-12 Journal: Liver transplantation : official publication of th [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome Antibody Response coronavirus dose homologous Liver transplantation Messenger RNA recipient vaccination [DOI] 10.1002/lt.26472 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialRandomized Controlled Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Adenovirus Administered Adverse reaction agency assigned boost booster dose booster vaccination Booster vaccine China Chinese Controlled trial CoronaVac COVID-19 vaccine development dose evaluate foundation geometric mean titre GMT GMTs Health Heterologous High dose homologous homologous or heterologous immunogenic inactivated incidence individual infection with SARS-CoV-2 intramuscular vaccination Jiangsu Laboratory less live SARS-CoV-2 low dose NAbs natural neutralising antibody Open-label participant primary endpoint priming Program randomised Randomly receive Registered reported Safe Safety SARS-CoV-2 SARS-CoV-2 vaccine Science serum significantly significantly higher Trial vaccination viral particle virus waning immunity [DOI] 10.1016/S2213-2600(22)00087-X PMC 바로가기 [Article Type] Randomized Controlled Trial
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts이종 및 동종 COVID-19 백신의 내구성 향상Article Published on 2022-08-012022-09-11 Journal: JAMA Network Open [Category] SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S Adenovirus age Analysis Antibody Response Antibody responses Asian assays binding black BNT162b2 BNT162b2 vaccine boost Boston CD4+ T-cell CD8+ Cellular immune response cellular immune responses cohort study COVID-19 COVID-19 vaccine cytokine Data analysis declined elicited evaluate evaluated female Follow-up functional antibody response Heterologous heterologous prime-boost Hispanic homologous humoral humoral immune responses immune response immune responses immunization immunogenicity individual intracellular cytokine staining involved IQR Latino Massachusetts median Messenger RNA mRNA mRNA vaccine Neutralizing neutralizing antibodies titer neutralizing antibody occurred of BNT162b2 omicron outcome participant peaked potential benefit potential benefits prime-boost regimen rapid increase regimen repeated response SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants T-cell responses These data Vaccine was performed were assessed white [DOI] 10.1001/jamanetworkopen.2022.26335 PMC 바로가기 [Article Type] Article
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in SingaporeArticle Published on 2022-08-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI adjusted Against age Assessing BBIBP-CorV BNT162b2 booster cohort study Combination combinations CoronaVac COVID-19 COVID-19 vaccination death defined determine dose Effectiveness eligible Estimated greater homologous inactivated individual Infection intensive care Moderna mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 no significant difference Older omicron outcome Pfizer-BioNTech provided reduction Reinfection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant severe COVID-19 severe disease Sex Singapore Sinopharm Sinovac supplemental oxygen time interval vaccination Vaccine vaccine dose waned was determined were excluded women [DOI] 10.1001/jamanetworkopen.2022.28900 PMC 바로가기
Electrochemical genosensor for the specific detection of SARS-CoV-2SARS-CoV-2의 특정 검출을 위한 전기화학적 제노센서Article Published on 2022-08-012022-09-11 Journal: Talanta [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] alternative biotinylated capture caused cell cultures complex complexes coronavirus disease COVID-19 cultures detect Diagnosis diagnostic discrimination disease DNA-RNA followed by Genosensor homologous horseradish peroxidase imperative in vitro Increases limit of detection maleimide molecular mortality rate Nanobioconjugate pandemic Particles peroxidase probe probes respiratory respiratory viruses responsible SARS-CoV-2 SARS-CoV-2 cell SARS-CoV-2 detection sensitivity serological test Serological tests Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Signaling streptavidin Surveillance tested the patient virus [DOI] 10.1016/j.talanta.2022.123482 PMC 바로가기 [Article Type] Article
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination이종 및 동종 SARS-CoV-2 백신 접종에서 세포 및 체액성 면역 반응의 상호 의존성Observational Study Published on 2022-08-012022-09-11 Journal: Allergy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Anti-spike Antibody avidity association avidity blood sample Blood samples BNT162b2 booster booster vaccination cellular Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 group healthcare worker Heterologous homologous humoral Humoral and cellular immune responses humoral immune response humoral responses IgG levels immune immune response immune responses immunization interferon interferon-γ nCoV Neutralizing antibodies neutralizing antibody no significant differences Observational cohort study SARS-CoV-2 SARS-CoV-2 vaccination secondary immunization significant difference significant differences Spike protein T-cell T-cell activation T-cell Response T-cell responses unlikely vaccination [DOI] 10.1111/all.15247 PMC 바로가기 [Article Type] Observational Study